Journal: Reproduction (Cambridge, England)

Article Title: Molecular signatures to define spermatogenic cells in common marmoset (Callithrix jacchus).

doi: 10.1530/REP-11-0215

Figure Lengend Snippet: Figure 3 Immunofluorescence analyses of pluripotency-determining factors in marmoset ES cells and testis. (A) Immunocytochemistry of POU5F1, SOX2, and NANOG in marmoset ES cells. Insets represent the merged images with Hoechst 33342 staining. Scale bar, 50 mm. (B) Hematoxylin and eosin staining of marmoset testis: neonate (1 day old; No. I5230M), juvenile (10 months old; No. M5040), and adult (10 years old; No. I1749M). Scale bar, 50 mm. (C and D) One-day-old neonatal marmoset testis (No. I5230M) stained with anti-POU5F1, anti-SOX2, and anti-NANOG antibodies. Dot-lined circle shows a single seminiferous cord. Arrowheads indicate nuclear protein localization. Arrows point out background signals from the interstitium. (E and F) Ten-month-old juvenile marmoset testis (No. M5040) stained with anti-POU5F1, anti-SOX2, and anti- NANOG antibodies. Nuclei were stained with Hoechst 33342. Scale bar, 50 mm.

Article Snippet: The following primary antibodies were used: mouse anti-POU5F1 (clone 7F9.2) MAB (1/200), human/mouse SOX2 MAB (clone 245610) mouse IgG2A (1/200), rabbit anti-NANOG polyclonal antibody (1/200), rabbit anti-DDX4 polyclonal antibody (1/50, ab13840; Abcam, Cambridge, MA, USA), rabbit antiDAZL polyclonal antibody (1/100, ab34139; Abcam), and rabbit anti-SYCP3 polyclonal antibody (1/100, NB300-232; www.reproduction-online.org Novus, Littleton, CO, USA).

Techniques: Immunocytochemistry, Staining

Journal: Oncology reports

Article Title: Expression of NANOG in human gliomas and its relationship with undifferentiated glioma cells.

doi: 10.3892/or.2011.1308

Figure Lengend Snippet: Figure 3. Expression of NANOG in U87 parental attached cells and BTSCs in vitro. NANOG immunocytochemical staining in (A) U87 parental attached cells (magnification, x400) and (B) BTSCs (magnification, x400). (C) Western blot analysis of U87 parental attached cells and BTSCs (normal brain tissues as control). (E) Histogram representing the relative level of NANOG protein as determined by Western blot analysis (P<0.01, independent Student's t-test). (D) Expression of NANOG mRNA as determined by RT-PCR in U87 parental attached cells and BTSCs (removing the template as control). (F) Histogram representing the relative level of NANOG mRNA as determined by RT-PCR (P<0.01, independent Student's t-test).

Article Snippet: The primary antibodies used were as follows: mouse monoclonal anti-cD133 (Miltenyi, germany), rabbit polyclonal anti-gFAp, rabbit polyclonal anti-nse (ZsgB-BIo) and rabbit polyclonal anti-nAnog antibody (r&D systems, UsA).

Techniques: Expressing, In Vitro, Staining, Western Blot, Control, Reverse Transcription Polymerase Chain Reaction

Journal: Oncology reports

Article Title: Expression of NANOG in human gliomas and its relationship with undifferentiated glioma cells.

doi: 10.3892/or.2011.1308

Figure Lengend Snippet: Figure 4. Expression of NANOG in differential pathological grade glioma tissues in vivo. (A-H) NANOG immunohistochemical staining of paraffin sections of gliomas (magnification, x400). (A) Expression of NANOG in WHO Grade Ⅱ tissue; NANOG expression was primarily localized in the nuclei of tumor cells (black arrow). (C) Expression of NANOG in WHO Grade Ⅲ tissue; NANOG expression was primarily localized in the nuclei of tumor cells (black arrow). (E) Expression of NANOG in WHO Grade Ⅳ tissue; NANOG expression was primarily localized in the nuclei of tumor cells (black arrow), particularly tumor giant cells (blue arrow). However, cytoplasmic staining was also observed (red arrow). (G) Normal brain tissue. (B, D, F and H) Negative control using corresponding adjacent sections. (I) Western blot analysis of different pathological grade glioma tissues (normal brain tissues as control). (K) Histogram representing the relative level of NANOG protein as determined by Western blot analysis (P<0.01, ANOVA). (J) Expression of NANOG mRNA by RT-PCR in different pathological grade glioma tissues (normal brain tissues as control). (L) Histogram representing relative level of NANOG mRNA by RT-PCR (P<0.01, ANOVA).

Article Snippet: The primary antibodies used were as follows: mouse monoclonal anti-cD133 (Miltenyi, germany), rabbit polyclonal anti-gFAp, rabbit polyclonal anti-nse (ZsgB-BIo) and rabbit polyclonal anti-nAnog antibody (r&D systems, UsA).

Techniques: Expressing, In Vivo, Immunohistochemical staining, Staining, Negative Control, Western Blot, Control, Reverse Transcription Polymerase Chain Reaction

Journal: Oncology reports

Article Title: Expression of NANOG in human gliomas and its relationship with undifferentiated glioma cells.

doi: 10.3892/or.2011.1308

Figure Lengend Snippet: Figure 5. Coexpression of NANOG/CD133 and NANOG/GFAP by double-label immunohistochemical staining. (A) Coexpression of NANOG/CD133 in gliomas (magnification, x200). (B) Coexpression of NANOG/GFAP in gliomas (magnification, x200). (C) Coexpression of NANOG/CD133 in gliomas. NANOG+/CD133+ glioma cells were observed (black arrow) (magnification, x400). (D) Coexpression of NANOG/GFAP in gliomas. NANOG+/GFAP- glioma cells were observed (black arrow) (magnification, x400). (E) Histogram representing relative expression level of NANOG and CD133 in gliomas (P<0.01, ANOVA and Spearman rank-sum test). (F) Histogram representing the relative expression level of NANOG and GFAP in the gliomas (P<0.01, ANOVA and Spearman rank-sum test). N/C, NANOG/CD133. N/G, NANOG/GFAP.

Article Snippet: The primary antibodies used were as follows: mouse monoclonal anti-cD133 (Miltenyi, germany), rabbit polyclonal anti-gFAp, rabbit polyclonal anti-nse (ZsgB-BIo) and rabbit polyclonal anti-nAnog antibody (r&D systems, UsA).

Techniques: Immunohistochemical staining, Staining, Expressing